Revance Therapeutics enters into an exclusive distribution agreement with Teoxane SA

On January 10, 2020, Revance Therapeutics, Inc. (Nasdaq: RVNC) – a Silicon Valley based biotechnology innovator for aesthetic and therapeutic indications – announced entering into an agreement with Teoxane SA (a manufacturer of Hyaluronic Acid dermal fillers based in Geneva) for the exclusive distribution of FDA-approved RHA dermal fillers in the US, thereby gaining access to the growing USD 1.1 billion US filler market.

Lenz & Staehelin advised Revance Therapeutics, Inc. on the Swiss law aspects of the transaction. The team was led by Xavier Favre-Bulle and Sevan Antreasyan.

Published: 13 January 2020